Thomson Reuters And Lance Armstrong Foundation Provide Online Cancer Information

Cancer Profiler provides patients with treatment information on www.livestrong.org

Ann Arbor, MI May 2008 – More than 1.4 million people will be diagnosed with cancer this year, and they will confront the question, “what do I do now?” To increase cancer patients’ understanding of their medical treatment options, Thomson Reuters has partnered with the Lance Armstrong Foundation (LAF) to provide 20 Cancer Profiler tools on www.livestrong.org.

Now available under the Web site’s Cancer Support tab (www.livestrong.org/cancersupport), the Thomson Reuters Cancer Profiler tools allow patients and caregivers to enter detailed information on a diagnosis and receive treatment options and other information that can be used in the management of the condition. The online resource provides a step-by-step approach to help users better understand diagnostic tests, treatment options and, in some cases, possible outcomes based on the experience of similar people treated within clinical trials. All of the information is based on a database of peer-reviewed clinical research.
No other Internet offering produces such in-depth treatment information tailored to an individual’s specific diagnosis and clinical status. This individualized information helps patients have more informed discussions with their doctors, take charge of their health, and participate more fully in treatment decisions – with the aim of improving their medical prognosis.

“The Cancer Profilers provide invaluable support to the patient-physician discussion of treatment options,” said Dr. Debra L. Friedman, associate member director for the Survivorship Program at the Fred Hutchinson Cancer Research Center. “This support, focusing on treatment information that is relevant to a patient’s specific situation, is extremely helpful at a time when patients are faced with the fear and challenges of a cancer diagnosis.”

The Cancer Profiler tools use patented technology to lead users through an easy-to-follow questionnaire that matches the patient’s diagnosis, diagnostic results, and disease stage with the relevant treatment options.

“This tool significantly expands what we are able to offer those who visit www.livestrong.org in terms of personalized treatment options, awareness and education,” said Andy Miller, vice president of programs and policies for the LAF. “We are pleased to partner with Thomson Reuters to provide this invaluable information to help LAF visitors understand their cancer treatment options.”

Thomson Reuters’ Profiler treatment option tools provide customized information on more than 30 chronic diseases including cancer, cardiovascular, pulmonary and urologic conditions. They have been used by more than 1 million people on Web sites of the American Heart Association, American Lung Association, and academic and commercial healthcare organizations. To learn more, visit www.nexcura.com.